The drug that actually works for trigeminal neuralgia is carbamazepine, sold under the brand name Tegretol. It is the only FDA-approved medication for this condition, and it has held that distinction for decades. In placebo-controlled crossover studies, carbamazepine delivers roughly 75 percent pain relief compared to about 25 percent for placebo, and real-world initial response rates reach as high as 88.3 percent in published data from a study of 354 patients. For a condition often called the “suicide disease” because of the sheer desperation it causes, that level of efficacy is not just clinically significant — it is life-altering. Trigeminal neuralgia produces sudden, stabbing, electric shock-like facial pain that can be triggered by something as mundane as brushing your teeth, chewing food, or walking into cold air.
The episodes last seconds to minutes, but they are widely considered the most severe pain known to medicine. Imagine a bolt of lightning firing through your cheek every time you try to eat breakfast. That is the daily reality for people living with this disorder, and it is why finding a drug that genuinely works matters so much. This article covers what carbamazepine does and why it remains the gold standard, the better-tolerated alternative oxcarbazepine, second-line options for patients who cannot take either drug, emerging treatments in clinical trials, and what surgical options exist when medications fail altogether. If you or someone you care for is dealing with this kind of facial pain — particularly older adults already navigating cognitive decline or dementia — understanding these treatment pathways is essential for making informed decisions with a neurologist.
Table of Contents
- What Is Trigeminal Neuralgia and Why Is It So Difficult to Treat?
- How Carbamazepine Stops the Electric Shock Pain
- Oxcarbazepine — A Kinder Version of the Same Idea
- What to Try When First-Line Drugs Fall Short
- Serious Risks and Monitoring Requirements Caregivers Should Know
- New Drugs in the Pipeline That Could Change Treatment
- When Drugs Are Not Enough — Surgical Options
- Conclusion
- Frequently Asked Questions
What Is Trigeminal Neuralgia and Why Is It So Difficult to Treat?
Trigeminal neuralgia affects the trigeminal nerve, the fifth cranial nerve responsible for sensation across most of the face. When this nerve malfunctions — usually because a blood vessel is pressing against it at the brainstem — it begins firing pain signals without any real cause. The pain is not like a headache or a toothache. It arrives in sharp, electric bursts that can strike dozens of times per day. Prevalence sits at roughly 0.1 to 0.3 percent of the general population, with annual incidence in the United States running at 5.9 per 100,000 women and 3.4 per 100,000 men. The female-to-male ratio is approximately 3:2. What makes it especially relevant to older adults and dementia caregiving is the age curve.
Incidence rises sharply with age — from 0.1 per 100,000 in people under 20 to 23.1 per 100,000 in those 80 and older. That means the population most vulnerable to trigeminal neuralgia overlaps heavily with the population most affected by cognitive decline, Alzheimer’s disease, and other dementias. A person with moderate dementia who suddenly begins refusing food, flinching during face washing, or becoming agitated during oral care may actually be experiencing trigeminal neuralgia attacks they cannot articulate. Caregivers and clinicians need to keep this diagnosis on their radar. The difficulty in treatment comes from the nature of the pain itself. Standard painkillers — acetaminophen, ibuprofen, even opioids — do essentially nothing for trigeminal neuralgia. The pain originates from abnormal nerve signaling, not tissue damage or inflammation. That is why the treatment that works is an anticonvulsant, a drug originally designed to stop seizures, which happens to calm the same kind of hyperexcited nerve firing that produces this facial pain.
How Carbamazepine Stops the Electric Shock Pain
Carbamazepine is a voltage-gated sodium channel blocker. In plain terms, it works by stabilizing hyperexcited nerve membranes, keeping sodium channels locked in their inactivated states so they cannot fire the rapid, repetitive pain signals that define trigeminal neuralgia. Dosing typically ranges from 100 to 2,400 milligrams per day, titrated upward until pain is controlled or side effects become limiting. At effective doses, it provides improved pain relief in 70 to 75 percent of patients. However, carbamazepine is not without significant problems. Side effects occur in 43.6 percent of users.
Common complaints include dizziness, drowsiness, nausea, and cognitive dulling — that last one being particularly concerning for older adults who may already be dealing with memory issues or early-stage dementia. In 29.6 percent of patients, major side effects forced either treatment interruption or dose reduction. There is also a rare but serious risk of Stevens-Johnson syndrome, a potentially life-threatening skin reaction that requires immediate medical attention. Blood monitoring is standard practice during treatment because carbamazepine can suppress white blood cell counts and affect liver function. The other catch is that carbamazepine does not always keep working. some patients who respond well initially develop resistance to the drug anywhere between 2 months and 10 years after starting treatment. When that happens, the pain returns, and the search for an alternative begins. This is not a failure of the drug so much as a reality of how nerve pain conditions evolve over time, but it means that carbamazepine should be understood as a powerful first-line option rather than a permanent cure.
Oxcarbazepine — A Kinder Version of the Same Idea
Oxcarbazepine, marketed as Trileptal, works through a similar sodium channel blocking mechanism but is generally better tolerated. The American Academy of Neurology and the European Federation of Neurological Societies rate it as “probably effective” (Level B evidence), one step below carbamazepine’s Level A rating. But the clinical numbers tell an interesting story. In a head-to-head study, oxcarbazepine posted an initial response rate of 90.9 percent, and its complete response rate hit 67.9 percent compared to 42.9 percent for carbamazepine. Side effects caused treatment interruption in only 12.6 percent of patients on oxcarbazepine, roughly half the discontinuation rate seen with carbamazepine.
For older adults, especially those with any degree of cognitive impairment, oxcarbazepine’s milder side effect profile can make a meaningful difference. Less drowsiness and less cognitive fog mean a patient is more likely to stay on the medication long enough for it to work and less likely to experience worsened confusion that could be mistaken for dementia progression. Many neurologists now start with oxcarbazepine as a practical first choice, even though carbamazepine technically holds the stronger evidence rating and the only FDA approval. The limitation here is that oxcarbazepine is not FDA-approved specifically for trigeminal neuralgia — it is used off-label. Insurance coverage can sometimes be more complicated as a result, and some clinicians still default to carbamazepine because of its formal approval status. If your neurologist prescribes oxcarbazepine, it is worth understanding that this is a widely accepted, guideline-supported practice, not an experimental gamble.
What to Try When First-Line Drugs Fall Short
About 50 percent of trigeminal neuralgia patients in real-world practice require combination therapy — multiple medications used together — for adequate pain control. When carbamazepine or oxcarbazepine alone is not enough, or when side effects force a change, the second-line options include lamotrigine, baclofen, and gabapentin. Lamotrigine and baclofen are the traditional second-line agents recommended by treatment guidelines for patients who cannot tolerate the first-line drugs. Gabapentin has shown comparable efficacy to carbamazepine in a meta-analysis of 1,331 patients, with considerably fewer side effects, which makes it an increasingly attractive option — particularly for elderly patients already on multiple medications.
The tradeoff with gabapentin is that evidence supporting it specifically for trigeminal neuralgia is not as robust as the evidence for carbamazepine, so it tends to remain in the second-line category despite its tolerability advantages. The practical reality for many patients is a trial-and-error process. A neurologist may start with carbamazepine, switch to oxcarbazepine if side effects are too burdensome, add lamotrigine or baclofen as an adjunct if pain control remains incomplete, or try gabapentin as a standalone alternative. Each step involves balancing pain relief against side effect burden, and for patients with dementia or cognitive impairment, that balance requires especially careful monitoring. A drug that controls facial pain but worsens confusion may not represent a net improvement in quality of life.
Serious Risks and Monitoring Requirements Caregivers Should Know
Carbamazepine carries several risks that demand active monitoring, and caregivers of older adults should be aware of all of them. The Stevens-Johnson syndrome risk, while rare, is serious enough that the FDA recommends genetic testing for the HLA-B*1502 allele in patients of Asian ancestry before starting the drug, as this genetic variant dramatically increases the risk. Any new rash, fever, or mouth sores in a patient starting carbamazepine should be treated as a potential emergency. Blood work must be performed regularly — typically before starting the drug and at intervals during treatment — to monitor white blood cell counts, liver function, and sodium levels. Carbamazepine is also a potent inducer of liver enzymes, meaning it can reduce the effectiveness of other medications a patient may be taking.
This is a particular concern for older adults on blood thinners, heart medications, or other drugs with narrow therapeutic windows. The interaction profile of carbamazepine is extensive, and a pharmacist should review all concurrent medications before it is prescribed. For dementia caregivers specifically, watch for increased confusion, unsteadiness, or falls. These side effects can overlap with symptoms of dementia itself, making it difficult to distinguish drug effects from disease progression. If a patient’s cognitive function or mobility noticeably declines after starting carbamazepine or oxcarbazepine, that change should be reported to the prescribing physician promptly rather than attributed to the underlying dementia.
New Drugs in the Pipeline That Could Change Treatment
The treatment landscape for trigeminal neuralgia may be shifting. Basimglurant, also called NOE-101, is a selective mGluR5 inhibitor developed by Noema Pharma that received FDA Fast Track designation in October 2022. The LibraTN Phase II/III trial was initiated in July 2025 to assess its safety and efficacy, and the drug has shown favorable tolerability in over 1,000 subjects with no known abuse potential. Unlike carbamazepine, basimglurant works through an entirely different mechanism — glutamate receptor modulation rather than sodium channel blockade — which could make it effective for patients who have developed resistance to existing drugs.
Vixotrigine, also known as BIIB074, takes a more targeted approach to sodium channels. Rather than broadly blocking voltage-gated sodium channels the way carbamazepine does, vixotrigine selectively targets the Nav1.7 channel subtype, which is specifically involved in pain signaling. In Phase IIa trials, it reduced paroxysms by 45 percent, lowered daily pain scores by 50 percent, and decreased paroxysm severity by 26 percent compared to placebo. Phase 3 studies are planned. There is also early research into exemestane, an FDA-approved breast cancer drug, which increased NRF2 expression in trigeminal ganglion neurons in mice and decreased sensitivity to pain stimuli — a repurposing story still in preclinical stages but worth watching.
When Drugs Are Not Enough — Surgical Options
When medications fail or become intolerable, surgery becomes the next conversation. Microvascular decompression, or MVD, is the only surgical procedure that addresses the root cause of trigeminal neuralgia — the blood vessel compressing the trigeminal nerve at the brainstem. According to data published in the New England Journal of Medicine, MVD has an 80 to 90 percent immediate success rate, with 70 percent of patients still pain-free at 10 years. Recurrence drops below 2 percent per year after 5 years and below 1 percent per year after 10 years.
For patients who are not good candidates for open surgery — including many elderly patients or those with significant comorbidities — less invasive options exist. The OneRF Trigeminal Nerve Ablation System by NeuroOne received FDA 510(k) clearance in 2025 for radiofrequency lesioning of trigeminal nerve tissue, with a limited commercial launch planned for the fourth quarter of 2025. Radiofrequency ablation and other percutaneous procedures offer relief with lower surgical risk, though outcomes tend to be less durable than MVD. The decision between open surgery and ablation involves weighing the patient’s overall health, age, cognitive status, and willingness to accept surgical risk against the severity and persistence of their pain.
Conclusion
Trigeminal neuralgia remains one of the most painful conditions in medicine, but it is not untreatable. Carbamazepine is the only FDA-approved drug for the condition and delivers meaningful relief for the majority of patients who try it. Oxcarbazepine offers a better-tolerated alternative with comparable or even superior response rates in some studies.
For the roughly half of patients who need more than one drug, second-line agents like gabapentin, lamotrigine, and baclofen provide additional options, and surgical interventions like microvascular decompression offer long-term relief when medications fail. For families navigating both trigeminal neuralgia and cognitive decline, the key is working closely with a neurologist who understands the drug interaction risks and cognitive side effects that make this population uniquely vulnerable. New drugs like basimglurant and vixotrigine may eventually offer better-targeted treatments with fewer cognitive side effects, but as of March 2026, the proven path starts with carbamazepine or oxcarbazepine and escalates from there. If someone you care for is showing unexplained facial pain, food refusal, or agitation during face touching, ask their doctor about trigeminal neuralgia — it is treatable, and the right drug can bring genuine relief.
Frequently Asked Questions
Is trigeminal neuralgia related to dementia or Alzheimer’s disease?
Trigeminal neuralgia is not caused by dementia, but it disproportionately affects older adults — incidence reaches 23.1 per 100,000 in those over 80. The two conditions frequently coexist, and facial pain may go undiagnosed in patients who cannot clearly describe their symptoms due to cognitive impairment.
Can carbamazepine make dementia symptoms worse?
Yes, carbamazepine commonly causes drowsiness, dizziness, and cognitive dulling, which can mimic or worsen dementia symptoms. Oxcarbazepine tends to produce fewer cognitive side effects and may be a better choice for patients with existing cognitive impairment, though this decision should be made with a neurologist.
Why do regular painkillers not work for trigeminal neuralgia?
Trigeminal neuralgia pain comes from abnormal nerve signaling, not from tissue damage or inflammation. Standard painkillers like ibuprofen and even opioids target different pain pathways and have essentially no effect on the misfiring nerve signals that cause trigeminal neuralgia attacks.
How long does carbamazepine keep working?
Most patients respond well initially, with response rates reaching 88.3 percent. However, some patients develop resistance between 2 months and 10 years after starting treatment. When this happens, physicians typically adjust the dose, switch to an alternative medication, add a second drug, or consider surgical options.
Is surgery safe for elderly patients with trigeminal neuralgia?
Microvascular decompression has excellent long-term outcomes — 70 percent of patients are still pain-free at 10 years — but it is open brain surgery and carries higher risk for frail or elderly patients. Less invasive options like radiofrequency ablation, including the newly FDA-cleared OneRF system, offer lower-risk alternatives with somewhat less durable results.
